First volunteers dosed in colorectal cancer trial
Biotechnology company Larkspur Biosciences has dosed the first volunteers in the Phase I study of its treatment for microsatellite stable (MSS), colorectal cancer (CRC) and other solid tumours. LRK-4189 is an oral, first-in-class targeted protein degrader of the lipid kinase PIP4K2C. The drug triggers multiple killing mechanisms… Read More
